{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:29Z","timestamp":1794047489595,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285768","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T02:33:56Z","timestamp":1724294036000},"page":"228-233","source":"Crossref","is-referenced-by-count":6,"title":["Comparing the clinical trial efficacy &lt;i&gt;versus&lt;\/i&gt; real-world effectiveness of treatments for multiple myeloma: a population-based study"],"prefix":"10.3324","volume":"110","author":[{"given":"Alissa","family":"Visram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Kar-Wing","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Gayowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Venner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Lancman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaris","family":"Balitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Kouroukis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bruins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"71234","doi-asserted-by":"crossref","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018; 131(3):301-310.","DOI":"10.1182\/blood-2017-07-795047"},{"key":"71235","doi-asserted-by":"crossref","unstructured":"Durie BGM, Hoering A, Sexton R. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020; 10(5):53.","DOI":"10.1038\/s41408-020-0311-8"},{"key":"71236","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Palumbo A. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17(1):27-38.","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"71237","doi-asserted-by":"crossref","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-152.","DOI":"10.1056\/NEJMoa1411321"},{"key":"71238","doi-asserted-by":"crossref","unstructured":"Mateos MV, Sonneveld P, Hungria V. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020; 20(8):509-518.","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"71239","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ. Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020; 34(7):1875-1884.","DOI":"10.1038\/s41375-020-0711-6"},{"key":"71240","doi-asserted-by":"crossref","unstructured":"Miguel JS, Weisel K, Moreau P. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11):1055-1066.","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"71241","doi-asserted-by":"crossref","unstructured":"Orlowski RZ, Moreau P, Niesvizky R. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019; 19(8):522-530.","DOI":"10.1016\/j.clml.2019.04.018"},{"key":"71242","doi-asserted-by":"crossref","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018; 36(8):728-734.","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"71243","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Oriol A, Nahi H. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023; 41(8):1590-1599.","DOI":"10.1200\/JCO.22.00940"},{"key":"71244","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol. 2023; 41(8):1600-1609.","DOI":"10.1200\/JCO.21.02734"},{"key":"71245","doi-asserted-by":"crossref","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9.","DOI":"10.1186\/1471-2288-12-9"},{"key":"71246","doi-asserted-by":"crossref","unstructured":"Knauf W, Aldaoud A, Hutzschenreuter U. Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms. Ann Hematol. 2018; 97(12):2437-2445.","DOI":"10.1007\/s00277-018-3449-8"},{"key":"71247","doi-asserted-by":"crossref","unstructured":"Klausen TW, Gregersen H, Abildgaard N. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 2019; 33(2):546-549.","DOI":"10.1038\/s41375-018-0272-0"},{"key":"71248","doi-asserted-by":"crossref","unstructured":"Chari A, Romanus D, Palumbo A. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/ refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020; 20(1):8-17.","DOI":"10.1016\/j.clml.2019.09.625"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285768\/77477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285768\/77959","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11736\/77477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:11Z","timestamp":1794046031000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285768","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}